Bd reports q2 fiscal 2025 results; raises eps despite macro headwinds

financial highlights
- revenue: $5.3 billion (up 4.5% as reported, 6.0% currency-neutral, 0.9% organic)
- gaap eps: $1.07
- adjusted eps: $3.35
- margin expansion and operational efficiency drove earnings beat despite soft organic growth

strategic and operational updates
- bd to invest $2.5 billion over 5 years to expand u.s. manufacturing, reinforcing domestic supply resilience
- bd pyxis™ medstation es and alaris™ infusion system won 2025 best in klas awards, highlighting market leadership in medication management
- launch of hemosphere alta™ platform brings ai-driven clinical decision support to advanced patient monitoring
- fda clearance for phasix™ st umbilical hernia patch, first of its kind in bioabsorbable mesh
- clinical milestone for galaflex lite™ scaffold in breast implant revision surgery with first patient treated
- diagnostics unit gains fda clearance for integrated solution to detect antimicrobial resistance using bd phoenix™, bdxpert™, and synapsys™ informatics

guidance and outlook
- company reaffirmed full-year eps guidance; detailed tariff-related headwinds in updated projections
- bd continues to prioritize innovation and efficiency under its bd excellence operating model